Translational & Clinical Research (TACR) Program

翻译和临床研究 项目摘要/摘要 转化和临床研究(TACR)计划成立于2016年初，是一项前瞻性的计划， 积极应对翻译和临床癌症研究从以疾病为中心的持续转变 范式，并朝着跨病区创新发展。TACR表示之间的接口 基础科学计划和以临床为基础的针对疾病的研究小组，旨在加快 密歇根大学综合癌症中心开发的创新临床方法的翻译 (UMCCC)研究人员到临床。该计划由来自24个不同部门的69名成员组成 代表6所不同的学校和学院。2016年，TACR成员的年度总资产(DC)为2880万美元 癌症补助金，其中700万美元(24.3%)来自NCI，270万美元(9.4%)来自其他NIH，1260万美元(43.7%)， 完全经过同行评审。此外，TACR成员还得到了药品和设备公司的赠款支持 总资金为1450万美元(50.4%)。调查人员参与方案内和方案间的互动，并 积极与UMCCC其他项目的研究人员在大多数基础科学和癌症领域开展合作 控制和人口科学项目。会员共有出版物1423份，其中31.1%为 方案内和50.6%是方案间。TACR计划有三个主要的具体目标：i)使用 最先进的基因组方法，以发现促进患者护理的技术；ii)推进新型UMCCC 将概念和试剂转化为人体试验，以加快将实验室发现转化为临床；以及三) 开发和测试新的预测性生物标志物和疾病监测战略，以改善患者护理。

TRANSLATIONAL AND CLINICAL RESEARCH PROJECT SUMMARY/ABSTRACT The Translational and Clinical Research (TACR) Program was established in early 2016 as a forward-looking, proactive response to an ongoing shift in translational and clinical cancer research away from disease-centric paradigms, and toward cross-disease site innovation and development. TACR represents the interface between basic science Programs and the clinic-based, disease-specific research groups and is designed to expedite the translation of innovative clinical approaches developed by University of Michigan Comprehensive Cancer Center (UMCCC) researchers to the clinic. The program is comprised of 69 members from 24 different departments representing 6 different schools and colleges. In 2016, TACR members had a total of $28.8M in annual (DC) cancer grant funding, of which $7M (24.3%) is from NCI, $2.7M (9.4%) is from other NIH, and $12.6M (43.7%), is total peer-reviewed. In addition, TACR members are supported by grants from drug and device companies with total funding of $14.5M (50.4%). Investigators are involved in intra- and inter-programmatic interactions and actively collaborate with researchers in the other UMCCC programs within most of the Basic Science and Cancer Control and Population Sciences Programs. Members have a total of 1423 publications, of which 31.1% are intra-programmatic and 50.6% are inter-programmatic. The TACR program has three main Specific Aims: I) use state-of-the-art genomic approaches to make discoveries that advance patient care; II) Advance novel UMCCC concepts and agents into human trials to expedite the translation of laboratory discoveries to the clinic; and III) Develop and test new predictive biomarker and disease monitoring strategies for improving patient care.